Olympus Corporation (OLYMY)
| Market Cap | 14.03B +0.8% |
| Revenue (ttm) | 6.43B +7.8% |
| Net Income | 481.61M -30.3% |
| EPS | 0.44 -28.0% |
| Shares Out | n/a |
| PE Ratio | 29.12 |
| Forward PE | n/a |
| Dividend | 0.19 (1.66%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 2,342 |
| Open | 13.30 |
| Previous Close | 13.23 |
| Day's Range | 13.30 - 13.37 |
| 52-Week Range | 8.08 - 13.73 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About Olympus
Olympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through two segments, “Gastrointestinal Solutions and Surgical & Interventional Solutions. The company offers gastrointestinal Solutions products offer gastrointestinal endoscopes, gastroenterology devices, and medical services. The Surgical & Interventional Solutions provides urology, respiratory, surgical endoscopes, energy devices, ENT products, and gynecology product... [Read more]
Financial Performance
In fiscal year 2026, Olympus's revenue was 1.01 trillion, an increase of 1.34% compared to the previous year's 997.33 billion. Earnings were 68.17 billion, a decrease of -42.16%.
Financial numbers in JPY Financial StatementsNews
Olympus Earnings Call Transcript: Q1 2027
Strong U.S. performance and disciplined cost management drove margin expansion and offset headwinds from China and shipment holds. Shipment holds are expected to ease in the second half, and operating model changes are delivering SG&A savings.
Olympus Quarterly report: Q1 2027
Olympus has published its Q1 2027 quarterly earnings report on August 7, 2026.
Olympus Slides: Q1 2027
Olympus has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 7, 2026.
Olympus downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Akinori Ueda downgraded Olympus (OLYMY) to Neutral from Buy with a 2,050 yen price target The firm cites the stock’s recent outperformance for the downgrade. Published first…
Olympus Earnings Call Transcript: Q4 2026
Q4 delivered strong sales in North America and robust global performance, with new products driving growth. Strategic review of the surgical segment is underway, and quality remediation costs are set to decline as Project Elevate concludes.
Olympus Slides: Q4 2026
Olympus has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 12, 2026.
Olympus Quarterly report: Q4 2026
Olympus has published its Q4 2026 quarterly earnings report on May 12, 2026.
Olympus Slides: Company presentation
Olympus has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
Olympus Earnings Call Transcript: Q3 2026
Revenue guidance was revised down due to ship holds and U.S. GI execution issues, but Q4 growth is expected as corrective actions take effect. FDA-related product holds and recalls impacted costs and margins, but long-term margin and growth targets remain unchanged.
Olympus Quarterly report: Q3 2026
Olympus has published its Q3 2026 quarterly earnings report on February 13, 2026.
Olympus Slides: Q3 2026
Olympus has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 13, 2026.
Olympus Transcript: 44th Annual J.P. Morgan Healthcare Conference
Olympus outlined a vision for endoscopy-enabled care driven by innovation, AI, and robotics, targeting 3–5% annual revenue growth and margin expansion. Strategic priorities include product launches, China localization, disciplined M&A, and operational efficiency, with a focus on patient outcomes and market leadership.
Olympus Slides: 44th Annual J.P. Morgan Healthcare Conference
Olympus has posted slides in relation to its latest quarterly earnings report, which was published on January 13, 2026.
Olympus Earnings Call Transcript: Q2 2026
The medium-term plan targets steady revenue and margin growth, driven by innovation, restructuring, and disciplined capital allocation. Guidance is conservative, with upside potential from new product launches and market recovery, especially in China and the US.
Olympus Quarterly report: Q2 2026
Olympus has published its Q2 2026 quarterly earnings report on November 7, 2025.
Olympus Slides: Q2 2026
Olympus has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 7, 2025.
Olympus Transcript: Status update
A new strategy focuses on expanding endoscopy-enabled care through innovation, AI, and robotics, targeting 5% annual revenue growth and 100 basis points of margin improvement per year. Structural changes and a division-led model aim to boost efficiency, while investments in technology and partnerships drive future growth.
Olympus Slides: Status update
Olympus has posted slides in relation to its latest quarterly earnings report, which was published on November 6, 2025.
Olympus Earnings Call Transcript: Q1 2026
Q1 FY2026 saw a 12% revenue decline and a 65% drop in adjusted operating profit, driven by tough comps, delayed purchases, and regulatory/tariff headwinds. Management expects recovery from Q2 with new product launches, cost control, and local production in China.
Olympus Quarterly report: Q1 2026
Olympus has published its Q1 2026 quarterly earnings report on August 8, 2025.
Olympus Slides: Q1 2026
Olympus has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 8, 2025.
Olympus Earnings Call Transcript: Q4 2025
FY2025 saw record revenue and strong profit growth, led by North America, despite China headwinds and supply chain disruptions. FY2026 guidance anticipates steady growth, increased R&D investment, higher dividends, and a major share buyback, with U.S. tariff risks being closely monitored.
Olympus Quarterly report: Q4 2025
Olympus has published its Q4 2025 quarterly earnings report on May 13, 2025.
Olympus Slides: Q4 2025
Olympus has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on May 13, 2025.
Olympus Earnings Call Transcript: Q3 2025
Revenue grew 9% year-on-year, led by strong North American and SEA performance, but China’s ongoing challenges prompted a downward revision in full-year guidance. Adjusted operating profit and margins improved, with management targeting a return to 20%+ margins in the medium term.